Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
January 5, 2023
Kaden Venugopal, Nefissa Bedri
5 citations
Introduction: Psilocybin (the active compound found in “magic mushrooms”) has been an area of recent focus in the academic and psychiatric community on account of its potential in treating a spectrum of substance use and concurrent disorders (SUCDs). This paper posits a literature review of the current research pertaining to psilocybin in treating alcohol use disorder (AUD) through a form of...
Pain Practice
January 4, 2023
Tim Willegers, Anke Reuser, Cornelis Kramers et al.
38 citations
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chronic pain is a common and complex problem, with an unknown etiology. Psychedelics like lysergic acid diethylamide (LSD) and psilocybin, may play a role in the management of chronic pain. Through activation of the serotonin‐2A (5‐HT2A) receptor,...
Open Journal of Medical Psychology
2023
John R. Rossiter
1 citation
Objective: Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therapeutic Goods Administration, is planning to allow approved psychiatrists, as of July 1, 2023, to prescribe psilocybin to treat depression and MDMA to treat post-traumatic stress disorder, a move precipitated by the U.S. Food and Drug Administration’s...
The Meducator
2023
Alam Mehrjerdi Zahra, Bhavana Soma
2 citations
Psilocybin is a naturally occurring compound present in numerous mushroom species characterised by its hallucinogenic and psychedelic effects. Although it has a negative reputation, psilocybin has demonstrated therapeutic potential for treating mental health disorders by allowing the brain to make new neural connections which help the neural pathways adapt and break out of certain cognitive...
Hop and Medicinal Plants
December 28, 2022
Vanessa Eveline Vlaic, Andreea Ona
The therapeutic use of the substance psilocin produced by the fungi from the genus named Psilocybe has been an interesting but also controversial topic of discussion among researchers since the 1950s until now. These fungi can synthesize several alkaloids such as psilocybin, which has hallucinogenic properties, but also muscarine, which is a toxic substance that stimulates that part of the...
Contemporary Clinical Trials
December 1, 2022
Kelley C O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et al.
24 citations
Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a...
The Brown University Psychopharmacology Update
November 3, 2022
Two sessions of psilocybin‐assisted psychotherapy resulted in reduced heavy‐drinking days and other alcohol‐related problems relative to placebo plus psychotherapy in a randomized trial involving patients with alcohol use disorder (AUD). There were no serious adverse events associated with psilocybin administration, and no signs of psychotic disturbances. Study results were published online...
Alcoholism & Drug Abuse Weekly
October 14, 2022
Alison Knopf
The beneficial effects of psilocybin‐assisted psychotherapy on alcohol use disorder (AUD) are significant, based on a study published in JAMA Psychiatry last month. In general, psychedelic medications have been a focus of research, but less is known about psilocybin, and it has been 40 years since the studies with lysergic acid diethylamide (LSD) provided double the remissions as comparison...
JAMA
October 4, 2022
Anita Slomski
6 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck...
BMJ Open
October 1, 2022
Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Tobias Søgaard Juul et al.
21 citations
Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meaningful experiences that may spur a positive change in drinking behaviour when administered in a...